Condition: Beta Lactam Allergy · Hematologic Malignancy · Sponsor: Abramson Cancer Center at Penn Medicine
The overall goal of the RENEW-IN intervention is to assess the impact of a BL allergy delabeling intervention on antibiotic use and clinical outcomes in patients with a hematologic malignancy.
This description comes directly from the study's public registry record.
Ebbing Lautenbach, MD,MPH,MSCE · 215-898-6977 · ebbing@pennmedicine.upenn.edu
Always discuss trial participation with your own doctor first.
| Hospital of the University of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07133074